Invasive GIST Originating in the Stomach/Small Intestine Is More Common in Men, Study Shows
February 19th 2021Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.
Tesetaxel Plus Capecitabine Combo Improves PFS in HR+ Metastatic Breast Cancer
December 15th 2020Treatment with tesetaxel plus a reduced dose of capecitabine improved progression-free survival in patients with HER2–, HR+ metastatic breast cancer compared with the FDA-approved dose of capecitabine alone.
Venetoclax/Rituximab Shows 5-Year Survival Benefit in Relapsed/Refractory CLL
December 5th 2020Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.